Oncology Based In Vivo Contract Research Organization (CRO) Market
Oncology Based In Vivo Contract Research Organization (CRO) Market
Segments - Oncology Based In-vivo Contract Research Organization (CRO) Market by Models (Xenograft, Syngeneic Model, and Patient Derived Xenograft), Indications (Solid Tumors, Blood Cancer, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-2267
| 4.2 Rating
| 76 Reviews
| 215 Pages
| Format :
Report Description
The global oncology based in-vivo contract research organization (CRO) market size was USD 1.8 Billion in 2022 and is likely to reach USD 3.66 Billion by 2031 , expanding at a CAGR of 8.2% during 2023–2031. The growth of the market is attributed to the growing government funding for research purposes, increasing cases of cancer, and rising expertise for cancer by CROs.
In-vivo CRO is an oncology-based CRO that specializes in preclinical drug development, testing, and infection diagnosis research. Pharmaceutical firms have been extending their product pipeline to develop and manufacture new molecules in order to preserve significant benefits and patent products in the marketplace. Thus, it is propelling the demand for research organizations in the In-vivo contract. According to a report on Global Health and Aging Study published by the World Health Organization (WHO), the number of people aged 65 and above is estimated to increase from 524 million in 2010 to around 1.5 billion by 2050, with emerging nations accounting for a large portion of the increase. Primary chronic diseases such as cancer have had the greatest impact on the senior population, particularly in high-income countries.
The COVID-19 pandemic outbreak had adversely impacted the market as majority of the pharmaceutical companies shifted their focus on vaccine development or manufacturing diagnostic kits for testing the virus. Research firms and clients were having a pause or cancel further studies. Recently, a report on CROs estimated that approximately 40% drop in new clinical trials was reported in the first half of the year when the pandemic was erupted. However, as the pandemic got subsided over several regions; the market players are trying to find ways to keep their work moving despite the pandemic's challenges.
Market Trends, Drivers, Restraints, and Opportunities
-
Increasing geriatric population further leads to rising cases of chronic disorders globally. This is expected to fuel the market growth.
-
Rising number of pharmaceutical companies with strong product portfolio is expected to boost the market in the coming years.
-
Increasing adoption of advanced technology along with growing internet usage in the healthcare sector that facilitates high level oncology treatment acts as a key driver of the market.
-
High cost involved in the establishment of the in-vivo CRO process concerning issues around unsuccessful treatment method are major challenges expected to hamper the market growth in the near future.
Scope of the Report
The report on the global oncology based In-vivo CRO market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Oncology Based In-vivo CRO Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Models (Xenograft, Syngeneic Model, and Patient Derived Xenograft) and Indications (Solid Tumors, Blood Cancer, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Crown Bioscience; Xentech; Charles River Laboratory; Living Tumor Laboratory; The Jackson Laboratory; ICON Plc.; Wuxi AppTec.; Eurofins Scientific; Taconic Biosciences; Covance; EVOTEC; MI Bioresearch, Inc.; and Champion Oncology, Inc. |
Market Segment Insights
Patient derived xenograft segment is expected to expand at a rapid pace
Based on models, the global oncology based in-vivo CRO market is segmented into xenograft, syngeneic model, and patient derived xenograft. The patient derived xenograft (PDX) segment is expected to expand at a rapid pace during the forecast period attributed to the benefits of integrating the targeted tumor cells within the animal models. The most frequent approaches for verifying the results acquired in in-vivo studies of cancer treatment candidates are PDX mouse models. A personalized strategy, which is the current trending medicine, is driving preclinical studies for cancer. Crown Bioscience, Inc.'s Guizhong Lui published a document outlining the advantages of employing a PDX model in mice. The models have a stronger association between the studied outcome and the final treatment effects found in clinical trial participants. Thus, it has become the best choice among researchers.
Solid tumor segment is projected to register a considerable CAGR
On the basis of Indications, the market is segregated as solid tumors, blood cancer, and others. The solid tumor segment is projected to register a considerable CAGR during the forecast period owing to the factors such as increasing incidence rate and boosting research for tumors in organs such as liver and breast along with technological advancement offered by major industry players.
Cancer that develops in the organs, muscles, or bones is known as a solid tumor. Carcinomas and sarcomas are the terms used to describe these tumors. The rising global incidence of cancer as well as expanding interest from several world bodies such as WHO in assessing its prevalence, causative agents, and treatment possibilities, are boosting the segment growth.
North America is anticipated to constitute a key market share
In terms of regions, the global oncology based in- vivo CRO market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period attributing to t factors such as huge investment on research and development along with the presence of well-established players in the region.
On the other hand, the market of Asia Pacific is anticipated to exhibit substantial growth in the coming years. The rapidly growing healthcare infrastructure, as well as the incorporation of research activities by medium and small scale enterprises are key factors supporting the regional market expansion. Furthermore, the increasing number of patients in the region combined with the region's flexible regulatory restrictions are projected to attract the existing CROs in the region.
Segments
The global oncology based in-vivo CRO market has been segmented on the basis of
Models
- Xenograft
- Syngeneic Model
- Patient Derived Xenograft
Indications
- Solid Tumors
- Blood Cancer
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Crown Bioscience
- Xentech
- Charles River Laboratory
- Living Tumor Laboratory
- The Jackson Laboratory
- ICON Plc.
- Wuxi AppTec.
- Eurofins Scientific
- Taconic Biosciences
- Covance
- EVOTEC
- MI Bioresearch, Inc.
- Champion Oncology, Inc.
Competitive Landscape
Some of the major players competing in the global oncology based in- vivo CRO market are Crown Bioscience; Xentech; Charles River Laboratory; Living Tumor Laboratory; The Jackson Laboratory; ICON Plc.; Wuxi AppTec.; Eurofins Scientific; Taconic Biosciences; Covance; EVOTEC; MI Bioresearch, Inc.; and Champion Oncology, Inc. These major players are implementing various marketing strategies, such as capital investments, merger & acquisitions, and new product development to enhance their position in the market.
Taconic Biosciences and Cellaria Biosciences had entered into a partnership in March 2015 in order to advance the development and widespread usage of PDX models to meet the existing unmet needs, and further strategic initiatives include the creation of new PDX-based models databases. Crown Bioscience, Inc. is a tech-platform company that specializes in inflammation, metabolic diseases, and oncology medication discovery and development. The firm offers preclinical immunotherapy research platforms to aid in the successful translation of immunotherapeutic from the laboratory to the clinic, including models for evaluating CAR-T treatments, syngeneic, and humanize-able vaccines.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncology Based In-vivo Contract Research Organization (CRO) Market Market - Supply Chain
4.5. Global Oncology Based In-vivo Contract Research Organization (CRO) Market Market Forecast
4.5.1. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Absolute $ Opportunity
5. Global Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
6. North America Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
7. Latin America Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
8. Europe Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
9. Asia Pacific Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
10. Middle East & Africa Oncology Based In-vivo Contract Research Organization (CRO) Market Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Oncology Based In-vivo Contract Research Organization (CRO) Market Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Oncology Based In-vivo Contract Research Organization (CRO) Market Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Oncology Based In-vivo Contract Research Organization (CRO) Market Market: Market Share Analysis
11.2. Oncology Based In-vivo Contract Research Organization (CRO) Market Distributors and Customers
11.3. Oncology Based In-vivo Contract Research Organization (CRO) Market Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Crown Bioscience
11.4.2. Xentech
11.4.3. Charles River Laboratory
11.4.4. Living Tumor Laboratory
11.4.5. The Jackson Laboratory
11.4.6. ICON Plc.
11.4.7. Wuxi AppTec.
11.4.8. Eurofins Scientific
11.4.9. Taconic Biosciences
11.4.10. Covance
11.4.11. EVOTEC
11.4.12. MI Bioresearch, Inc.
11.4.13. Champion Oncology, Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
